Risk factors for systemic reactions to allergen immunotherapy
| Autor: | Pilar Hernandez-Weigand, Alfredo Iglesias-Cadarso |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Allergen immunotherapy
medicine.medical_treatment Immunology MEDLINE Cross Reactions Sex Factors Sex factors Risk Factors medicine Hypersensitivity Product Surveillance Postmarketing Immunology and Allergy Animals Humans Medication Errors Desensitization (medicine) Clinical Trials as Topic business.industry Age Factors Immunotherapy Clinical Practice Systemic reaction Desensitization Immunologic Practice Guidelines as Topic business |
| Zdroj: | Current opinion in allergy and clinical immunology. 11(6) |
| ISSN: | 1473-6322 |
| Popis: | To update safety information regarding allergen-specific immunotherapy (ASIT) in clinical practice and highlight the risk factors associated with the adverse reactions, product and each dose.Efforts in recent years have focused on increasing our understanding of the efficacy and safety of ASIT, especially the sublingual variety (SLIT), in multicenter studies. Moreover, new Clinical Practice Guidelines (CPGs) and an international consensus concerning ASIT have been published recently. Although no deaths as a result of subcutaneous immunotherapy or SLIT have been reported in the last 2 years, systemic reactions mainly arising from administration errors still appear. Recent studies support the safety of new forms of specific immunotherapy.An understanding of the risk factors for each patient, product and dose, and the implementation of CPGs are the main factors that could improve the safety of ASIT. The standardization of all procedures for prescribing and administering ASIT, and the systematic collection of standardized safety data in a multicenter database (postmarketing surveillance), may be required to generate new information on the safety of ASIT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|